Form 4: Sana Biotechnology Officer Susan D. Wyrick Reports Stock Transactions

Susan D. Wyrick, Acting Chief Financial Officer and Principal Accounting Officer of Sana Biotechnology, reports acquisition and disposal of common stock and derivative securities.

Summary

• On March 7, 2025, Susan D. Wyrick acquired 3,250 shares of common stock through the vesting of restricted stock units.
• On March 10, 2025, she disposed of 836 shares of common stock at a price of $2.56.
• As of March 10, 2025, Wyrick beneficially owns 157,395 shares of common stock.
• On March 6, 2025, Wyrick was granted 41,667 restricted stock units and an option to buy 187,500 shares of common stock at an exercise price of $2.55.
• The restricted stock units vest in four equal installments starting March 6, 2026.
• The stock options vest as to 25% on March 6, 2026, and then in 36 equal monthly installments.
• As of March 7, 2025, 3,250 restricted stock units vested, and the remaining units will vest in three equal installments on each of March 7, 2026, 2027 and 2028.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions by an officer. The grants are positive, but the disposal is slightly negative, balancing out the overall sentiment.

Positives

• The granting of restricted stock units and stock options to an officer aligns her interests with those of the shareholders.
• The vesting schedules for the restricted stock units and stock options incentivize continued service to the company.

Negatives

• The disposal of 836 shares could be interpreted negatively, although the amount is relatively small compared to her total holdings.

Risks

• The value of the stock options is dependent on the future performance of Sana Biotechnology's stock price.
• The vesting of the restricted stock units and stock options is contingent upon continued service to the company, creating a potential risk of forfeiture if employment is terminated.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the equity awards suggest an expectation of continued service and potential future value creation.

Industry Context

Stock transactions by company officers are a common occurrence and are closely monitored by investors for insights into management's confidence in the company's future prospects. The granting of equity awards is a typical practice to incentivize and retain key personnel in the biotechnology industry.

Comparison to Industry Standards

• Equity grants to officers are standard practice in the biotech industry, often structured with vesting schedules tied to continued employment.
• The size of the grants and vesting terms are generally comparable to those offered by similar-sized biotech companies to their executive teams.
• Companies like CRISPR Therapeutics and Editas Medicine also utilize stock options and restricted stock units as part of their compensation packages for key employees.

Stakeholder Impact

• The transactions may have a minor impact on shareholders' perception of the company, depending on how they interpret the officer's stock disposal.
• The equity grants incentivize the officer to work towards the long-term success of the company, benefiting all stakeholders.

Key Dates